AR036154A1 - Anticuerpos especificos de cd44v6. - Google Patents
Anticuerpos especificos de cd44v6.Info
- Publication number
- AR036154A1 AR036154A1 ARP020101830A ARP020101830A AR036154A1 AR 036154 A1 AR036154 A1 AR 036154A1 AR P020101830 A ARP020101830 A AR P020101830A AR P020101830 A ARP020101830 A AR P020101830A AR 036154 A1 AR036154 A1 AR 036154A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variants
- seq
- fragments
- variable region
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036154A1 true AR036154A1 (es) | 2004-08-18 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101830A AR036154A1 (es) | 2001-05-18 | 2002-05-17 | Anticuerpos especificos de cd44v6. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (https=) |
| JP (1) | JP2005504517A (https=) |
| CN (1) | CN1541226A (https=) |
| AR (1) | AR036154A1 (https=) |
| BR (1) | BR0210905A (https=) |
| CA (1) | CA2443437A1 (https=) |
| CZ (1) | CZ20033476A3 (https=) |
| EA (1) | EA200301169A1 (https=) |
| EC (1) | ECSP034838A (https=) |
| EE (1) | EE200300569A (https=) |
| HU (1) | HUP0400030A3 (https=) |
| MX (1) | MXPA03010523A (https=) |
| PE (1) | PE20021098A1 (https=) |
| PL (1) | PL365735A1 (https=) |
| SK (1) | SK15592003A3 (https=) |
| WO (1) | WO2002094879A1 (https=) |
| YU (1) | YU91403A (https=) |
| ZA (1) | ZA200307365B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| SG182191A1 (en) * | 2007-06-13 | 2012-07-30 | Zymogenetics Inc | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| SI2531527T1 (sl) | 2010-02-04 | 2014-07-31 | F. Hoffmann-La Roche Ag | Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| EP4114860A1 (en) * | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| EP4301782A1 (en) * | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| JPH08506801A (ja) * | 1992-11-20 | 1996-07-23 | アイシス・イノベーション・リミテッド | Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法 |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active IP Right Cessation
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Ceased
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1541226A (zh) | 2004-10-27 |
| WO2002094879A1 (en) | 2002-11-28 |
| CZ20033476A3 (cs) | 2004-05-12 |
| PL365735A1 (en) | 2005-01-10 |
| PE20021098A1 (es) | 2003-02-11 |
| EA200301169A1 (ru) | 2004-06-24 |
| HUP0400030A3 (en) | 2006-02-28 |
| ECSP034838A (es) | 2003-12-24 |
| YU91403A (sh) | 2006-05-25 |
| EE200300569A (et) | 2004-04-15 |
| CA2443437A1 (en) | 2002-11-28 |
| BR0210905A (pt) | 2004-06-08 |
| JP2005504517A (ja) | 2005-02-17 |
| HUP0400030A2 (hu) | 2004-04-28 |
| MXPA03010523A (es) | 2004-07-01 |
| ZA200307365B (en) | 2004-05-10 |
| EP1397387A1 (en) | 2004-03-17 |
| SK15592003A3 (sk) | 2004-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036154A1 (es) | Anticuerpos especificos de cd44v6. | |
| PE20050376A1 (es) | Anticuerpos dirigidos a m-csf | |
| ECSP044978A (es) | ANTICUERPOS HUMANOS ANTAGONISTAS CONTRA hTNFSF13b | |
| ATE510011T1 (de) | Neue pilzproteine und diese codierende nukleinsäuren | |
| ECSP14011269A (es) | Formulaciones de anticuerpos y proteínas de alta concentración | |
| AR047717A1 (es) | Anticuerpos dirigidos a c-met | |
| WO2002083171A3 (en) | Cancer treatment by using fap-alpha specific antibodies | |
| EA200801509A1 (ru) | Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7 | |
| CY1110848T1 (el) | Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| AR045056A1 (es) | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf | |
| AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PY0132240A (es) | Anticuerpos contra el receptor del factor de crecimiento similar a insulina | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| ATE444361T1 (de) | Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen | |
| ATE209680T1 (de) | Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| DE69329195D1 (de) | Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen | |
| JP2005504517A5 (https=) | ||
| TW200635946A (en) | Binding proteins specific for human matriptase | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| AR004360A1 (es) | Composiciones farmaceuticas para la terapia de carcinomas del epitelio plano y un agente para ser empleado en estas composicines farmaceuticas. | |
| ES8606411A1 (es) | Procedimiento para la determinacion de fibrina | |
| DE69832875D1 (de) | Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |